Royalty Pharma
Buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
Launch date
Employees
Market cap
AUD19.2b
Enterprise valuation
AUD27.0b (Public information from Sep 2024)
Share price
$28.21 RPRX
New York City New York (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.1b | 2.3b | 2.2b | 2.4b | 2.7b | 2.8b | 3.1b |
| % growth | 17 % | 8 % | (2 %) | 5 % | 13 % | 7 % | 8 % |
| EBITDA | 1.9b | 1.5b | 983m | 1.6b | 2.5b | 2.8b | 3.0b |
| % EBITDA margin | 89 % | 65 % | 44 % | 67 % | 96 % | 98 % | 99 % |
| Profit | 975m | 620m | 42.8m | 1.1b | 634m | 908m | 933m |
| % profit margin | 46 % | 27 % | 2 % | 48 % | 24 % | 32 % | 31 % |
| EV / revenue | 10.9x | 9.7x | 10.2x | 7.7x | 7.2x | 6.7x | 6.2x |
| EV / EBITDA | 12.3x | 14.9x | 23.2x | 11.6x | 7.5x | 6.9x | 6.2x |
| R&D budget | 26.0m | 200m | 177m | 52.0m | - | - | - |
| R&D % of revenue | 1 % | 9 % | 8 % | 2 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | - | |
| N/A | N/A | IPO | |
| N/A | N/A | - | |
* | $150m | Post IPO Equity | |
* | N/A | $1.5b | Post IPO Debt |
| Total Funding | - | ||
Related Content
Recent News about Royalty Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Royalty Pharma
Edit
exited
exited
exited
ACQUISITION by Ipsen Jun 2022
ACQUISITION by Pfizer Oct 2022
ACQUISITION by Royalty Pharma May 2012
